Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19 : An Observational Multicenter Study
© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
Several medications commonly used for a number of medical conditions share a property of functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical evidence suggest that the ASM/ceramide system may be central to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. We examined the potential usefulness of FIASMA use among patients hospitalized for severe coronavirus disease 2019 (COVID-19) in an observational multicenter study conducted at Greater Paris University hospitals. Of 2,846 adult patients hospitalized for severe COVID-19, 277 (9.7%) were taking an FIASMA medication at the time of their hospital admission. The primary end point was a composite of intubation and/or death. We compared this end point between patients taking vs. not taking an FIASMA medication in time-to-event analyses adjusted for sociodemographic characteristics and medical comorbidities. The primary analysis was a Cox regression model with inverse probability weighting (IPW). Over a mean follow-up of 9.2 days (SD = 12.5), the primary end point occurred in 104 patients (37.5%) receiving an FIASMA medication, and 1,060 patients (41.4%) who did not. Despite being significantly and substantially associated with older age and greater medical severity, FIASMA medication use was significantly associated with reduced likelihood of intubation or death in both crude (hazard ratio (HR) = 0.71, 95% confidence interval (CI) = 0.58-0.87, P < 0.001) and primary IPW (HR = 0.58, 95%CI = 0.46-0.72, P < 0.001) analyses. This association remained significant in multiple sensitivity analyses and was not specific to one particular FIASMA class or medication. These results show the potential importance of the ASM/ceramide system in COVID-19 and support the continuation of FIASMA medications in these patients. Double-blind controlled randomized clinical trials of these medications for COVID-19 are needed.
| Errataetall: |
CommentIn: Clin Pharmacol Ther. 2022 Feb;111(2):353. - PMID 34719015 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
Clinical pharmacology and therapeutics - 110(2021), 6 vom: 01. Dez., Seite 1498-1511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoertel, Nicolas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.1.4.12 |
|---|
| Anmerkungen: |
Date Completed 23.11.2021 Date Revised 28.03.2023 published: Print-Electronic CommentIn: Clin Pharmacol Ther. 2022 Feb;111(2):353. - PMID 34719015 Citation Status MEDLINE |
|---|
| doi: |
10.1002/cpt.2317 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325995990 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325995990 | ||
| 003 | DE-627 | ||
| 005 | 20231225193631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpt.2317 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM325995990 | ||
| 035 | |a (NLM)34050932 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoertel, Nicolas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19 |b An Observational Multicenter Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2021 | ||
| 500 | |a Date Revised 28.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Pharmacol Ther. 2022 Feb;111(2):353. - PMID 34719015 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
| 520 | |a Several medications commonly used for a number of medical conditions share a property of functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical evidence suggest that the ASM/ceramide system may be central to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. We examined the potential usefulness of FIASMA use among patients hospitalized for severe coronavirus disease 2019 (COVID-19) in an observational multicenter study conducted at Greater Paris University hospitals. Of 2,846 adult patients hospitalized for severe COVID-19, 277 (9.7%) were taking an FIASMA medication at the time of their hospital admission. The primary end point was a composite of intubation and/or death. We compared this end point between patients taking vs. not taking an FIASMA medication in time-to-event analyses adjusted for sociodemographic characteristics and medical comorbidities. The primary analysis was a Cox regression model with inverse probability weighting (IPW). Over a mean follow-up of 9.2 days (SD = 12.5), the primary end point occurred in 104 patients (37.5%) receiving an FIASMA medication, and 1,060 patients (41.4%) who did not. Despite being significantly and substantially associated with older age and greater medical severity, FIASMA medication use was significantly associated with reduced likelihood of intubation or death in both crude (hazard ratio (HR) = 0.71, 95% confidence interval (CI) = 0.58-0.87, P < 0.001) and primary IPW (HR = 0.58, 95%CI = 0.46-0.72, P < 0.001) analyses. This association remained significant in multiple sensitivity analyses and was not specific to one particular FIASMA class or medication. These results show the potential importance of the ASM/ceramide system in COVID-19 and support the continuation of FIASMA medications in these patients. Double-blind controlled randomized clinical trials of these medications for COVID-19 are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a SMPD1 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.4.12 |2 NLM | |
| 650 | 7 | |a Sphingomyelin Phosphodiesterase |2 NLM | |
| 650 | 7 | |a EC 3.1.4.12 |2 NLM | |
| 700 | 1 | |a Sánchez-Rico, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Gulbins, Erich |e verfasserin |4 aut | |
| 700 | 1 | |a Kornhuber, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Carpinteiro, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Lenze, Eric J |e verfasserin |4 aut | |
| 700 | 1 | |a Reiersen, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a Abellán, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a de la Muela, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Vernet, Raphaël |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Cougoule, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Beeker, Nathanaël |e verfasserin |4 aut | |
| 700 | 1 | |a Neuraz, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Gorwood, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarado, Jesús M |e verfasserin |4 aut | |
| 700 | 1 | |a Meneton, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Limosin, Frédéric |e verfasserin |4 aut | |
| 700 | 0 | |a AP-HP / Université de Paris / INSERM COVID-19 research collaboration, AP-HP COVID CDR Initiative, “Entrepôt de Données de Santé” AP-HP Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Ancel, Pierre-Yves |e investigator |4 oth | |
| 700 | 1 | |a Bauchet, Alain |e investigator |4 oth | |
| 700 | 1 | |a Beeker, Nathanaël |e investigator |4 oth | |
| 700 | 1 | |a Benoit, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Bernaux, Mélodie |e investigator |4 oth | |
| 700 | 1 | |a Bellamine, Ali |e investigator |4 oth | |
| 700 | 1 | |a Bey, Romain |e investigator |4 oth | |
| 700 | 1 | |a Bourmaud, Aurélie |e investigator |4 oth | |
| 700 | 1 | |a Breant, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Burgun, Anita |e investigator |4 oth | |
| 700 | 1 | |a Carrat, Fabrice |e investigator |4 oth | |
| 700 | 1 | |a Caucheteux, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Champ, Julien |e investigator |4 oth | |
| 700 | 1 | |a Cormont, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Daniel, Christel |e investigator |4 oth | |
| 700 | 1 | |a Dubiel, Julien |e investigator |4 oth | |
| 700 | 1 | |a Ducloas, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Esteve, Loic |e investigator |4 oth | |
| 700 | 1 | |a Frank, Marie |e investigator |4 oth | |
| 700 | 1 | |a Garcelon, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Gramfort, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Griffon, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Grisel, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Guilbaud, Martin |e investigator |4 oth | |
| 700 | 1 | |a Hassen-Khodja, Claire |e investigator |4 oth | |
| 700 | 1 | |a Hemery, François |e investigator |4 oth | |
| 700 | 1 | |a Hilka, Martin |e investigator |4 oth | |
| 700 | 1 | |a Sophie Jannot, Anne |e investigator |4 oth | |
| 700 | 1 | |a Lambert, Jerome |e investigator |4 oth | |
| 700 | 1 | |a Layese, Richard |e investigator |4 oth | |
| 700 | 1 | |a Leblanc, Judith |e investigator |4 oth | |
| 700 | 1 | |a Lebouter, Léo |e investigator |4 oth | |
| 700 | 1 | |a Lemaitre, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Leprovost, Damien |e investigator |4 oth | |
| 700 | 1 | |a Lerner, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Levi Sallah, Kankoe |e investigator |4 oth | |
| 700 | 1 | |a Maire, Aurélien |e investigator |4 oth | |
| 700 | 1 | |a Mamzer, Marie-France |e investigator |4 oth | |
| 700 | 1 | |a Martel, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Mensch, Arthur |e investigator |4 oth | |
| 700 | 1 | |a Moreau, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Neuraz, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Orlova, Nina |e investigator |4 oth | |
| 700 | 1 | |a Paris, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Rance, Bastien |e investigator |4 oth | |
| 700 | 1 | |a Ravera, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Rozes, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Salamanca, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Sandrin, Arnaud |e investigator |4 oth | |
| 700 | 1 | |a Serre, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Tannier, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Treluyer, Jean-Marc |e investigator |4 oth | |
| 700 | 1 | |a van Gysel, Damien |e investigator |4 oth | |
| 700 | 1 | |a Varoquaux, Gaël |e investigator |4 oth | |
| 700 | 1 | |a Vie, Jill Jen |e investigator |4 oth | |
| 700 | 1 | |a Wack, Maxime |e investigator |4 oth | |
| 700 | 1 | |a Wajsburt, Perceval |e investigator |4 oth | |
| 700 | 1 | |a Wassermann, Demian |e investigator |4 oth | |
| 700 | 1 | |a Zapletal, Eric |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology and therapeutics |d 1960 |g 110(2021), 6 vom: 01. Dez., Seite 1498-1511 |w (DE-627)NLM000015318 |x 1532-6535 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2021 |g number:6 |g day:01 |g month:12 |g pages:1498-1511 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpt.2317 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 2021 |e 6 |b 01 |c 12 |h 1498-1511 | ||